ArticleJournal of the National Cancer Institute2020

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Ruitao Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.